Client Work

LSK Technologies Inc. acquired by Nicoya Lifesciences Inc.

Reading Time 1 minute read
Share

Overview

Client

LSK Technologies Inc.

On May 2, 2022, Nicoya Lifesciences ("Nicoya"), a global innovator of digital proteomics solutions for diagnostics and biotherapeutic discovery, announced the acquisition of LSK Technologies Inc. ("LSK"), a University of Toronto startup decentralizing laboratory testing with their "lab-in-a-box" platform. LSK's technology enables nucleic acid and protein testing of versatile samples at any time, generating results in 30 minutes while providing real time access to laboratory-grade results.

Fasken advised LSK in connection with its sale to Nicoya with a team comprised of Will Shaw, Ryan Schnier and Laura Fetter.

Jurisdiction

  • Ontario

Team

  • Will Shaw, Partner | Co-leader, Technology, Media and Telecommunications and Co-leader, Emerging Technology, Toronto, ON, +1 416 865 4554, wshaw@fasken.com
  • Laura Fetter, Counsel | Emerging Technology & Venture Capital, Toronto, ON, +1 416 865 4450, lfetter@fasken.com
Will Shaw Toronto Lawyer Will Shaw Partner | Co-leader, Technology, Media and Telecommunications and Co-leader, Emerging Technology Toronto, ON +1 416 865 4554
Laura Fetter Director of Innovation Laura Fetter Counsel | Emerging Technology & Venture Capital Toronto, ON +1 416 865 4450